



Company Overview

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum's first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

[Sign up here](#) to receive notices about press releases and SEC filings.

Iterum Therapeutics Reports First Quarter 2019 Financial Results

May 14 2019, 7:00 AM EDT

Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019

Apr 11 2019, 7:30 AM EDT

Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 25 2019, 7:00 AM EDT

Stock Overview

Symbol	ITRM
Exchange	Nasdaq
Market Cap	101.02m
Last Price	\$7.03
52-Week	\$4.70 - \$13.00

05/20/2019 03:59 PM EDT

Investor Relations

ir@iterumtx.com

Management Team

Corey N. Fishman

Chief Executive Officer

Michael Dunne, MD

Chief Scientific Officer

Judith M. Matthews

Chief Financial Officer

Benjamin M. Pe

Vice President Operations

John J. White

Vice President Business Development & Supply Chain

Tom Loughman, PhD

Vice President and CMC Head

Iterum Therapeutics plc

200 S Wacker Drive
Suite 2550
Chicago, IL 60606
USA

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.